Callahan Advisors LLC Purchases 3,415 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Callahan Advisors LLC increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 109.3% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 6,540 shares of the biopharmaceutical company's stock after purchasing an additional 3,415 shares during the quarter. Callahan Advisors LLC's holdings in Gilead Sciences were worth $604,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in GILD. nVerses Capital LLC purchased a new position in Gilead Sciences during the third quarter worth about $25,000. HHM Wealth Advisors LLC grew its position in Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 154 shares in the last quarter. Valued Wealth Advisors LLC grew its position in Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 161 shares in the last quarter. YANKCOM Partnership purchased a new position in Gilead Sciences during the fourth quarter worth about $28,000. Finally, Decker Retirement Planning Inc. purchased a new position in Gilead Sciences during the fourth quarter worth about $29,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

GILD has been the subject of several recent analyst reports. UBS Group boosted their target price on Gilead Sciences from $70.00 to $96.00 and gave the stock a "neutral" rating in a research report on Thursday, November 21st. JPMorgan Chase & Co. lifted their price target on Gilead Sciences from $105.00 to $115.00 and gave the stock an "overweight" rating in a research note on Wednesday, January 29th. Morgan Stanley lifted their price target on Gilead Sciences from $113.00 to $123.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 12th. DZ Bank raised Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price target for the company in a research note on Thursday, February 13th. Finally, Daiwa America raised Gilead Sciences to a "hold" rating in a research note on Monday, November 18th. Eleven research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $102.08.

Insider Buying and Selling

In related news, insider Merdad Parsey sold 164,211 shares of the company's stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total value of $15,094,275.12. Following the transaction, the insider now directly owns 80,801 shares of the company's stock, valued at approximately $7,427,227.92. This represents a 67.02 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares in the company, valued at $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 713,000 shares of company stock worth $67,945,181 in the last 90 days. Insiders own 0.16% of the company's stock.

Gilead Sciences Trading Down 0.1 %

GILD traded down $0.08 during midday trading on Friday, reaching $109.95. 9,729,048 shares of the company's stock traded hands, compared to its average volume of 7,379,648. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The stock has a market capitalization of $137.03 billion, a price-to-earnings ratio of 297.16, a P/E/G ratio of 0.71 and a beta of 0.18. The firm has a fifty day moving average of $95.41 and a two-hundred day moving average of $88.73. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $111.03.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Friday, March 14th. This represents a $3.16 annualized dividend and a dividend yield of 2.87%. This is an increase from Gilead Sciences's previous quarterly dividend of $0.77. Gilead Sciences's dividend payout ratio is presently 832.43%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.